speb/financial-data huggingface dataset:
GENI balance_sheet (quarterly, 2025-09-30) — Total Debt: 30176000.00
GENI balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 722530000.00
GENI income_statement (quarterly, 2025-09-30) — Total Expenses: 189221000.00
GENI balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 326570000.00
GENI balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 582699000.00
GENI balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 57275000.00
GENI income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: -25605000.00
GENI income_statement (quarterly, 2025-09-30) — Total Other Finance Cost: 138000.00
GENI balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 1606000.00
GENI income_statement (quarterly, 2025-09-30) — Total Unusual Items: -10147000.00
GENI income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: -10147000.00
GENI balance_sheet (quarterly, 2025-09-30) — Tradeand Other Payables Non Current: 15384000.00
GENI balance_sheet (quarterly, 2025-09-30) — Treasury Shares Number: 4105948.00
GENI balance_sheet (quarterly, 2025-09-30) — Treasury Stock: 17653000.00
GENI balance_sheet (quarterly, 2025-09-30) — Working Capital: 197106000.00
GENI income_statement (annual, 2025-12-31) — +Operating Expense: 295221000.00
GENI income_statement (quarterly, 2025-12-31) — +Operating Expense: 88544000.00
GENI income_statement (annual, 2025-12-31) — +Total Revenue: 669489000.00
GENI income_statement (quarterly, 2025-12-31) — +Total Revenue: 240496000.00
GENI balance_sheet (annual, 2025-12-31) — Accounts Payable: 112246000.00
GENI balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 112246000.00
GENI balance_sheet (annual, 2025-12-31) — Accounts Receivable: 130340000.00
GENI balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 130340000.00
GENI balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -26781000.00
GENI balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -26781000.00
GENI balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 1992257000.00
GENI balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 1992257000.00
GENI balance_sheet (annual, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -5511000.00
GENI balance_sheet (quarterly, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -5511000.00
GENI income_statement (annual, 2025-12-31) — Basic Average Shares: 254757802.00
GENI income_statement (quarterly, 2025-12-31) — Basic Average Shares: 259563131.00
GENI income_statement (annual, 2025-12-31) — Basic EPS: -0.44
GENI income_statement (quarterly, 2025-12-31) — Basic EPS: -0.08
GENI cash_flow (annual, 2025-12-31) — Beginning Cash Position: 135239000.00
GENI cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 207792000.00
GENI balance_sheet (annual, 2025-12-31) — Buildings And Improvements: 3844000.00
GENI balance_sheet (quarterly, 2025-12-31) — Buildings And Improvements: 3844000.00
GENI cash_flow (annual, 2025-12-31) — Capital Expenditure: -80894000.00
GENI cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -19316000.00
GENI cash_flow (annual, 2025-12-31) — Capital Expenditure Reported: -56967000.00
GENI cash_flow (quarterly, 2025-12-31) — Capital Expenditure Reported: -12301000.00
GENI balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 30495000.00
GENI balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 30495000.00
GENI balance_sheet (annual, 2025-12-31) — Capital Stock: 2505000.00
GENI balance_sheet (quarterly, 2025-12-31) — Capital Stock: 2505000.00
GENI balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 280559000.00
GENI balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 280559000.00
GENI balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 280559000.00
GENI balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 280559000.00
GENI cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: 143979000.00
GENI cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: -4000.00
GENI cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: -92908000.00
GENI cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -19316000.00
GENI cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: 86395000.00
GENI cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: 88954000.00
GENI cash_flow (annual, 2025-12-31) — Change In Account Payable: 75585000.00
GENI cash_flow (quarterly, 2025-12-31) — Change In Account Payable: 52326000.00
GENI cash_flow (annual, 2025-12-31) — Change In Accrued Expense: 31345000.00
GENI cash_flow (quarterly, 2025-12-31) — Change In Accrued Expense: 30421000.00
GENI cash_flow (annual, 2025-12-31) — Change In Other Current Assets: -7473000.00
GENI cash_flow (quarterly, 2025-12-31) — Change In Other Current Assets: 587000.00
GENI cash_flow (annual, 2025-12-31) — Change In Other Current Liabilities: -1321000.00
GENI cash_flow (quarterly, 2025-12-31) — Change In Other Current Liabilities: -1501000.00
GENI cash_flow (annual, 2025-12-31) — Change In Other Working Capital: 19312000.00
GENI cash_flow (quarterly, 2025-12-31) — Change In Other Working Capital: -1680000.00
GENI cash_flow (annual, 2025-12-31) — Change In Payable: 75585000.00
GENI cash_flow (quarterly, 2025-12-31) — Change In Payable: 52326000.00
GENI cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: 106930000.00
GENI cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 82747000.00
GENI cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: -30923000.00
GENI cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: -9577000.00
GENI cash_flow (annual, 2025-12-31) — Change In Receivables: -71022000.00
GENI cash_flow (quarterly, 2025-12-31) — Change In Receivables: -1809000.00
GENI cash_flow (annual, 2025-12-31) — Change In Working Capital: 15503000.00
GENI cash_flow (quarterly, 2025-12-31) — Change In Working Capital: 68767000.00
GENI cash_flow (annual, 2025-12-31) — Changes In Account Receivables: -44296000.00
GENI cash_flow (quarterly, 2025-12-31) — Changes In Account Receivables: 1833000.00
GENI cash_flow (annual, 2025-12-31) — Changes In Cash: 137466000.00
GENI cash_flow (quarterly, 2025-12-31) — Changes In Cash: 69634000.00
GENI balance_sheet (annual, 2025-12-31) — Common Stock: 2505000.00
GENI balance_sheet (quarterly, 2025-12-31) — Common Stock: 2505000.00
GENI balance_sheet (annual, 2025-12-31) — Common Stock Equity: 724475000.00
GENI balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 724475000.00
GENI cash_flow (annual, 2025-12-31) — Common Stock Issuance: 144000000.00
GENI cash_flow (quarterly, 2025-12-31) — Common Stock Issuance: 0.00
GENI income_statement (annual, 2025-12-31) — Cost Of Revenue: 515647000.00
GENI income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 172063000.00
GENI balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 118017000.00
GENI balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 118017000.00
GENI balance_sheet (annual, 2025-12-31) — Current Assets: 549683000.00
GENI balance_sheet (quarterly, 2025-12-31) — Current Assets: 549683000.00
GENI balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 5024000.00
GENI balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 5024000.00
GENI balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 5024000.00
GENI balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 5024000.00
GENI balance_sheet (annual, 2025-12-31) — Current Deferred Assets: 1140000.00
GENI balance_sheet (quarterly, 2025-12-31) — Current Deferred Assets: 1140000.00
GENI balance_sheet (annual, 2025-12-31) — Current Deferred Liabilities: 97098000.00
GENI balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 97098000.00
GENI balance_sheet (annual, 2025-12-31) — Current Deferred Revenue: 97098000.00
GENI balance_sheet (quarterly, 2025-12-31) — Current Deferred Revenue: 97098000.00
GENI balance_sheet (annual, 2025-12-31) — Current Liabilities: 352883000.00
GENI balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 352883000.00
GENI balance_sheet (annual, 2025-12-31) — Current Provisions: 4800000.00
GENI balance_sheet (quarterly, 2025-12-31) — Current Provisions: 4800000.00
GENI cash_flow (annual, 2025-12-31) — Deferred Income Tax: -7068000.00
GENI cash_flow (quarterly, 2025-12-31) — Deferred Income Tax: -4706000.00
GENI cash_flow (annual, 2025-12-31) — Deferred Tax: -7068000.00
GENI cash_flow (quarterly, 2025-12-31) — Deferred Tax: -4706000.00
GENI cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 70519000.00
GENI cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 20084000.00
GENI cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 70519000.00
GENI cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 20084000.00
GENI income_statement (annual, 2025-12-31) — Diluted Average Shares: 254757802.00
GENI income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 259563131.00
GENI income_statement (annual, 2025-12-31) — Diluted EPS: -0.44
GENI income_statement (quarterly, 2025-12-31) — Diluted EPS: -0.08
GENI income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -111581000.00
GENI income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -20621000.00
GENI cash_flow (annual, 2025-12-31) — Dividends Received Cfi: 2787000.00
GENI cash_flow (quarterly, 2025-12-31) — Dividends Received Cfi: 0.00
GENI income_statement (annual, 2025-12-31) — EBIT: -141379000.00
GENI income_statement (quarterly, 2025-12-31) — EBIT: -20111000.00
GENI income_statement (annual, 2025-12-31) — EBITDA: -70860000.00
GENI income_statement (quarterly, 2025-12-31) — EBITDA: -27000.00
GENI income_statement (annual, 2025-12-31) — Earnings From Equity Interest Net Of Tax: 3657000.00
GENI income_statement (quarterly, 2025-12-31) — Earnings From Equity Interest Net Of Tax: 802000.00
GENI cash_flow (annual, 2025-12-31) — Earnings Losses From Equity Investments: -3657000.00
GENI cash_flow (quarterly, 2025-12-31) — Earnings Losses From Equity Investments: -802000.00
GENI cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: 7854000.00
GENI cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: 3133000.00
GENI cash_flow (annual, 2025-12-31) — End Cash Position: 280559000.00
GENI cash_flow (quarterly, 2025-12-31) — End Cash Position: 280559000.00
GENI cash_flow (annual, 2025-12-31) — Financing Cash Flow: 143979000.00
GENI cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: -4000.00
GENI cash_flow (annual, 2025-12-31) — Free Cash Flow: 5501000.00
GENI cash_flow (quarterly, 2025-12-31) — Free Cash Flow: 69638000.00
GENI income_statement (annual, 2025-12-31) — Gain On Sale Of Ppe: 33000.00
GENI income_statement (quarterly, 2025-12-31) — Gain On Sale Of Ppe: 7000.00
GENI income_statement (annual, 2025-12-31) — Gain On Sale Of Security: 33567000.00
GENI income_statement (quarterly, 2025-12-31) — Gain On Sale Of Security: 1845000.00
GENI balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -53526000.00
GENI balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -53526000.00
GENI income_statement (annual, 2025-12-31) — General And Administrative Expense: 207972000.00
GENI income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 63267000.00
GENI balance_sheet (annual, 2025-12-31) — Goodwill: 338049000.00
GENI balance_sheet (quarterly, 2025-12-31) — Goodwill: 338049000.00
GENI balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 482252000.00
GENI balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 482252000.00
GENI balance_sheet (annual, 2025-12-31) — Gross Accounts Receivable: 135851000.00
GENI balance_sheet (quarterly, 2025-12-31) — Gross Accounts Receivable: 135851000.00
GENI balance_sheet (annual, 2025-12-31) — Gross PPE: 87424000.00
GENI balance_sheet (quarterly, 2025-12-31) — Gross PPE: 87424000.00
GENI income_statement (annual, 2025-12-31) — Gross Profit: 153842000.00
GENI income_statement (quarterly, 2025-12-31) — Gross Profit: 68433000.00
GENI cash_flow (annual, 2025-12-31) — Income Tax Paid Supplemental Data: 4606000.00
GENI cash_flow (quarterly, 2025-12-31) — Income Tax Paid Supplemental Data: 1603000.00
GENI balance_sheet (annual, 2025-12-31) — Income Tax Payable: 1276000.00
GENI balance_sheet (quarterly, 2025-12-31) — Income Tax Payable: 1276000.00
GENI cash_flow (annual, 2025-12-31) — Interest Paid Supplemental Data: 3967000.00
GENI cash_flow (quarterly, 2025-12-31) — Interest Paid Supplemental Data: 1343000.00
GENI balance_sheet (annual, 2025-12-31) — Inventory: 284000.00
GENI balance_sheet (quarterly, 2025-12-31) — Inventory: 284000.00
GENI balance_sheet (annual, 2025-12-31) — Invested Capital: 724475000.00
GENI balance_sheet (quarterly, 2025-12-31) — Invested Capital: 724475000.00
GENI cash_flow (annual, 2025-12-31) — Investing Cash Flow: -92908000.00
GENI cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -19316000.00
GENI balance_sheet (annual, 2025-12-31) — Investments And Advances: 32585000.00
GENI balance_sheet (quarterly, 2025-12-31) — Investments And Advances: 32585000.00
GENI cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 144000000.00
GENI cash_flow (quarterly, 2025-12-31) — Issuance Of Capital Stock: 0.00
GENI balance_sheet (annual, 2025-12-31) — Line Of Credit: 0.00
GENI balance_sheet (quarterly, 2025-12-31) — Line Of Credit: 0.00
GENI balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 25471000.00
GENI balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 25471000.00
GENI balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 25471000.00
GENI balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 25471000.00
GENI cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -21000.00
GENI cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: -4000.00
GENI balance_sheet (annual, 2025-12-31) — Long Term Equity Investment: 32585000.00
GENI balance_sheet (quarterly, 2025-12-31) — Long Term Equity Investment: 32585000.00
GENI balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 16219000.00
GENI balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 16219000.00
GENI cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: -14841000.00
GENI cash_flow (quarterly, 2025-12-31) — Net Business Purchase And Sale: 0.00
GENI cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: 144000000.00
GENI cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: 0.00
GENI cash_flow (annual, 2025-12-31) — Net Foreign Currency Exchange Gain Loss: -33296000.00
GENI cash_flow (quarterly, 2025-12-31) — Net Foreign Currency Exchange Gain Loss: -2153000.00
GENI income_statement (annual, 2025-12-31) — Net Income: -111581000.00
GENI income_statement (quarterly, 2025-12-31) — Net Income: -20621000.00
GENI income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -111581000.00
GENI income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -20621000.00
GENI income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -111581000.00
GENI income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -20621000.00
GENI income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -111581000.00
GENI income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -20621000.00
GENI income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -111581000.00
GENI income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -20621000.00
GENI cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -111581000.00
GENI cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -20621000.00
GENI income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -111581000.00
GENI income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -20621000.00
GENI cash_flow (annual, 2025-12-31) — Net Intangibles Purchase And Sale: -2076000.00
GENI cash_flow (quarterly, 2025-12-31) — Net Intangibles Purchase And Sale: -817000.00
GENI income_statement (annual, 2025-12-31) — Net Interest Income: -6000.00
GENI income_statement (quarterly, 2025-12-31) — Net Interest Income: -861000.00
GENI cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: -21000.00
GENI cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: -4000.00
GENI cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: -21000.00
GENI cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: -4000.00
GENI income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: -6000.00
GENI income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -861000.00
GENI cash_flow (annual, 2025-12-31) — Net Other Investing Changes: 40000.00
GENI cash_flow (quarterly, 2025-12-31) — Net Other Investing Changes: 0.00
GENI balance_sheet (annual, 2025-12-31) — Net PPE: 60643000.00
GENI balance_sheet (quarterly, 2025-12-31) — Net PPE: 60643000.00
GENI cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -21851000.00
GENI cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: -6198000.00
GENI cash_flow (annual, 2025-12-31) — Net Short Term Debt Issuance: 0.00
GENI balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 242223000.00
GENI balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 242223000.00
GENI balance_sheet (annual, 2025-12-31) — Non Current Accounts Receivable: 824000.00
GENI balance_sheet (quarterly, 2025-12-31) — Non Current Accounts Receivable: 824000.00
GENI balance_sheet (annual, 2025-12-31) — Non Current Deferred Assets: 2705000.00
GENI balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Assets: 2705000.00
GENI balance_sheet (annual, 2025-12-31) — Non Current Deferred Liabilities: 7575000.00
GENI balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 7575000.00
GENI balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Assets: 1643000.00
GENI balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Assets: 1643000.00
GENI balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 7186000.00
GENI balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 7186000.00
GENI balance_sheet (annual, 2025-12-31) — Non Current Prepaid Assets: 1595000.00
GENI balance_sheet (quarterly, 2025-12-31) — Non Current Prepaid Assets: 1595000.00
GENI income_statement (annual, 2025-12-31) — Normalized EBITDA: -94511000.00
GENI income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 2618000.00
GENI income_statement (annual, 2025-12-31) — Normalized Income: -134735329.00
GENI income_statement (quarterly, 2025-12-31) — Normalized Income: -18221718.34
GENI cash_flow (annual, 2025-12-31) — Operating Cash Flow: 86395000.00
GENI cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 88954000.00
GENI cash_flow (annual, 2025-12-31) — Operating Gains Losses: -36986000.00
GENI cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: -2962000.00
GENI income_statement (annual, 2025-12-31) — Operating Income: -141379000.00
GENI income_statement (quarterly, 2025-12-31) — Operating Income: -20111000.00
GENI income_statement (annual, 2025-12-31) — Operating Revenue: 669489000.00
GENI income_statement (quarterly, 2025-12-31) — Operating Revenue: 240496000.00
GENI balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 246306291.00
GENI balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 246306291.00
GENI balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: -53526000.00
GENI balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: -53526000.00
GENI income_statement (annual, 2025-12-31) — Other Gand A: 207972000.00
GENI income_statement (quarterly, 2025-12-31) — Other Gand A: 63267000.00
GENI income_statement (annual, 2025-12-31) — Other Income Expense: 23651000.00
GENI income_statement (quarterly, 2025-12-31) — Other Income Expense: -2645000.00
GENI balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 144203000.00
GENI balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 144203000.00
GENI cash_flow (annual, 2025-12-31) — Other Non Cash Items: 5558000.00
GENI cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 1237000.00
GENI balance_sheet (annual, 2025-12-31) — Other Non Current Liabilities: 3611000.00
GENI balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 3611000.00
GENI balance_sheet (annual, 2025-12-31) — Other Payable: 13636000.00
GENI balance_sheet (quarterly, 2025-12-31) — Other Payable: 13636000.00
GENI balance_sheet (annual, 2025-12-31) — Other Properties: 67361000.00
GENI balance_sheet (quarterly, 2025-12-31) — Other Properties: 67361000.00
GENI balance_sheet (annual, 2025-12-31) — Other Receivables: 59886000.00
GENI balance_sheet (quarterly, 2025-12-31) — Other Receivables: 59886000.00
GENI balance_sheet (annual, 2025-12-31) — Payables: 127944000.00
GENI balance_sheet (quarterly, 2025-12-31) — Payables: 127944000.00
GENI balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 245961000.00
GENI balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 245961000.00
GENI balance_sheet (annual, 2025-12-31) — Prepaid Assets: 66150000.00
GENI balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 66150000.00
GENI income_statement (annual, 2025-12-31) — Pretax Income: -117734000.00
GENI income_statement (quarterly, 2025-12-31) — Pretax Income: -23617000.00
GENI cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: 0.00
GENI balance_sheet (annual, 2025-12-31) — Properties: 0.00
GENI balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
GENI cash_flow (annual, 2025-12-31) — Provisionand Write Offof Assets: 1908000.00
GENI cash_flow (quarterly, 2025-12-31) — Provisionand Write Offof Assets: 1633000.00
GENI cash_flow (annual, 2025-12-31) — Purchase Of Business: -14841000.00
GENI cash_flow (quarterly, 2025-12-31) — Purchase Of Business: 0.00
GENI cash_flow (annual, 2025-12-31) — Purchase Of Intangibles: -2076000.00
GENI cash_flow (quarterly, 2025-12-31) — Purchase Of Intangibles: -817000.00
GENI cash_flow (annual, 2025-12-31) — Purchase Of PPE: -21851000.00
GENI cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -6198000.00
GENI balance_sheet (annual, 2025-12-31) — Receivables: 201550000.00
GENI balance_sheet (quarterly, 2025-12-31) — Receivables: 201550000.00
GENI income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 515647000.00
GENI income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 172063000.00
GENI income_statement (annual, 2025-12-31) — Reconciled Depreciation: 70519000.00
GENI income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 20084000.00
GENI cash_flow (annual, 2025-12-31) — Repayment Of Debt: -21000.00
GENI cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: -4000.00
GENI income_statement (annual, 2025-12-31) — Research And Development: 31087000.00
GENI income_statement (quarterly, 2025-12-31) — Research And Development: 8472000.00
GENI balance_sheet (annual, 2025-12-31) — Restricted Cash: 0.00
GENI balance_sheet (quarterly, 2025-12-31) — Restricted Cash: 0.00
GENI income_statement (annual, 2025-12-31) — Restructuring And Mergern Acquisition: 9949000.00
GENI income_statement (quarterly, 2025-12-31) — Restructuring And Mergern Acquisition: 4497000.00
GENI balance_sheet (annual, 2025-12-31) — Retained Earnings: -1199108000.00
GENI balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -1199108000.00
GENI income_statement (annual, 2025-12-31) — Selling And Marketing Expense: 56162000.00
GENI income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: 16805000.00
GENI income_statement (annual, 2025-12-31) — Selling General And Administration: 264134000.00
GENI income_statement (quarterly, 2025-12-31) — Selling General And Administration: 80072000.00
GENI balance_sheet (annual, 2025-12-31) — Share Issued: 250412239.00
GENI balance_sheet (quarterly, 2025-12-31) — Share Issued: 250412239.00
GENI cash_flow (annual, 2025-12-31) — Short Term Debt Payments: 0.00
GENI income_statement (annual, 2025-12-31) — Special Income Charges: -9916000.00
GENI income_statement (quarterly, 2025-12-31) — Special Income Charges: -4490000.00
GENI cash_flow (annual, 2025-12-31) — Stock Based Compensation: 148542000.00
GENI cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 25522000.00
GENI balance_sheet (annual, 2025-12-31) — Stockholders Equity: 724475000.00
GENI balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 724475000.00
GENI balance_sheet (annual, 2025-12-31) — Tangible Book Value: 242223000.00
GENI balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 242223000.00
GENI income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: 496671.00
GENI income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -245718.34
GENI income_statement (annual, 2025-12-31) — Tax Provision: -2496000.00
GENI income_statement (quarterly, 2025-12-31) — Tax Provision: -2194000.00
GENI income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.02
GENI income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.09
GENI balance_sheet (annual, 2025-12-31) — Taxes Receivable: 11324000.00
GENI balance_sheet (quarterly, 2025-12-31) — Taxes Receivable: 11324000.00
GENI balance_sheet (annual, 2025-12-31) — Total Assets: 1130287000.00
GENI balance_sheet (quarterly, 2025-12-31) — Total Assets: 1130287000.00
GENI balance_sheet (annual, 2025-12-31) — Total Capitalization: 724475000.00
GENI balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 724475000.00
GENI balance_sheet (annual, 2025-12-31) — Total Debt: 30495000.00
GENI balance_sheet (quarterly, 2025-12-31) — Total Debt: 30495000.00
GENI balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 724475000.00
GENI balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 724475000.00
GENI income_statement (annual, 2025-12-31) — Total Expenses: 810868000.00
GENI income_statement (quarterly, 2025-12-31) — Total Expenses: 260607000.00
GENI balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 405812000.00
GENI balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 405812000.00
GENI balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 580604000.00
GENI balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 580604000.00
GENI balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 52929000.00
GENI balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 52929000.00
GENI income_statement (annual, 2025-12-31) — Total Operating Income As Reported: -151328000.00
GENI income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: -24608000.00
GENI income_statement (annual, 2025-12-31) — Total Other Finance Cost: 6000.00
GENI income_statement (quarterly, 2025-12-31) — Total Other Finance Cost: 861000.00
GENI balance_sheet (annual, 2025-12-31) — Total Tax Payable: 2062000.00
GENI balance_sheet (quarterly, 2025-12-31) — Total Tax Payable: 2062000.00
GENI income_statement (annual, 2025-12-31) — Total Unusual Items: 23651000.00
GENI income_statement (quarterly, 2025-12-31) — Total Unusual Items: -2645000.00
GENI income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: 23651000.00
GENI income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -2645000.00
GENI balance_sheet (annual, 2025-12-31) — Tradeand Other Payables Non Current: 16272000.00
GENI balance_sheet (quarterly, 2025-12-31) — Tradeand Other Payables Non Current: 16272000.00
GENI balance_sheet (annual, 2025-12-31) — Treasury Shares Number: 4105948.00
GENI balance_sheet (quarterly, 2025-12-31) — Treasury Shares Number: 4105948.00
GENI balance_sheet (annual, 2025-12-31) — Treasury Stock: 17653000.00
GENI balance_sheet (quarterly, 2025-12-31) — Treasury Stock: 17653000.00
GENI balance_sheet (annual, 2025-12-31) — Working Capital: 196800000.00
GENI balance_sheet (quarterly, 2025-12-31) — Working Capital: 196800000.00
GENI income_statement (quarterly, 2026-03-31) — +Operating Expense: 78986000.00
GENI income_statement (quarterly, 2026-03-31) — +Total Revenue: 187952000.00
GENI balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 61250000.00
GENI balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 109896000.00
GENI balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 2010131000.00
GENI balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -6100000.00
GENI cash_flow (quarterly, 2026-03-31) — Asset Impairment Charge: 1735000.00
GENI income_statement (quarterly, 2026-03-31) — Basic Average Shares: 269373708.00
GENI income_statement (quarterly, 2026-03-31) — Basic EPS: -0.21
GENI cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 280559000.00
GENI cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -17697000.00
GENI cash_flow (quarterly, 2026-03-31) — Capital Expenditure Reported: -12275000.00
GENI balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 30550000.00
GENI balance_sheet (quarterly, 2026-03-31) — Capital Stock: 2617000.00
GENI balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 197444000.00
GENI balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 197444000.00
GENI cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 0.00
GENI cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -14176000.00
GENI cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -66413000.00
GENI cash_flow (quarterly, 2026-03-31) — Change In Account Payable: -50996000.00
GENI cash_flow (quarterly, 2026-03-31) — Change In Accrued Expense: -8372000.00
GENI cash_flow (quarterly, 2026-03-31) — Change In Other Current Assets: 2687000.00
GENI cash_flow (quarterly, 2026-03-31) — Change In Other Current Liabilities: -9994000.00
GENI cash_flow (quarterly, 2026-03-31) — Change In Other Working Capital: -27715000.00
GENI cash_flow (quarterly, 2026-03-31) — Change In Payable: -50996000.00
GENI cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: -59368000.00
GENI cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: 16848000.00
GENI cash_flow (quarterly, 2026-03-31) — Change In Receivables: 25288000.00
GENI cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -52254000.00
GENI cash_flow (quarterly, 2026-03-31) — Changes In Account Receivables: 21369000.00
GENI cash_flow (quarterly, 2026-03-31) — Changes In Cash: -80589000.00
GENI balance_sheet (quarterly, 2026-03-31) — Common Stock: 2617000.00
GENI balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 695099000.00
GENI cash_flow (quarterly, 2026-03-31) — Common Stock Issuance: 0.00
GENI income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 144628000.00
GENI balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 112916000.00
GENI balance_sheet (quarterly, 2026-03-31) — Current Assets: 437233000.00
GENI balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 5011000.00
GENI balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 5011000.00
GENI balance_sheet (quarterly, 2026-03-31) — Current Deferred Assets: 1225000.00
GENI balance_sheet (quarterly, 2026-03-31) — Current Deferred Liabilities: 74991000.00
GENI balance_sheet (quarterly, 2026-03-31) — Current Deferred Revenue: 74602000.00
GENI balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 273957000.00
GENI cash_flow (quarterly, 2026-03-31) — Deferred Income Tax: -452000.00
GENI cash_flow (quarterly, 2026-03-31) — Deferred Tax: -452000.00
GENI cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 20980000.00
GENI cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 20980000.00
GENI income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 269373708.00
GENI income_statement (quarterly, 2026-03-31) — Diluted EPS: -0.21
GENI income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -55470000.00
GENI cash_flow (quarterly, 2026-03-31) — Dividends Received Cfi: 3521000.00
GENI income_statement (quarterly, 2026-03-31) — EBIT: -54670000.00
GENI income_statement (quarterly, 2026-03-31) — EBITDA: -33690000.00
GENI income_statement (quarterly, 2026-03-31) — Earnings From Equity Interest Net Of Tax: 43000.00
GENI cash_flow (quarterly, 2026-03-31) — Earnings Losses From Equity Investments: -43000.00
GENI cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: -2526000.00
GENI cash_flow (quarterly, 2026-03-31) — End Cash Position: 197444000.00
GENI cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 0.00
GENI cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -84110000.00
GENI income_statement (quarterly, 2026-03-31) — Gain On Sale Of Ppe: -73000.00
GENI income_statement (quarterly, 2026-03-31) — Gain On Sale Of Security: -9697000.00
GENI balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: -45418000.00
GENI income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 53915000.00
GENI balance_sheet (quarterly, 2026-03-31) — Goodwill: 338049000.00
GENI balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 481077000.00
GENI balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 115996000.00
GENI balance_sheet (quarterly, 2026-03-31) — Gross PPE: 62915000.00
GENI income_statement (quarterly, 2026-03-31) — Gross Profit: 43324000.00
GENI cash_flow (quarterly, 2026-03-31) — Income Tax Paid Supplemental Data: 984000.00
GENI balance_sheet (quarterly, 2026-03-31) — Income Tax Payable: 1241000.00
GENI income_statement (quarterly, 2026-03-31) — Interest Expense: 928000.00
GENI income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 928000.00
GENI cash_flow (quarterly, 2026-03-31) — Interest Paid Supplemental Data: 1216000.00
GENI balance_sheet (quarterly, 2026-03-31) — Inventory: 401000.00
GENI balance_sheet (quarterly, 2026-03-31) — Invested Capital: 695099000.00
GENI cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -14176000.00
GENI balance_sheet (quarterly, 2026-03-31) — Investments And Advances: 30943000.00
GENI cash_flow (quarterly, 2026-03-31) — Issuance Of Capital Stock: 0.00
GENI balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 25539000.00
GENI balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 25539000.00
GENI cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: 0.00
GENI cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: 0.00
GENI cash_flow (quarterly, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: 9338000.00
GENI income_statement (quarterly, 2026-03-31) — Net Income: -55470000.00
GENI income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -55470000.00
GENI income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -55470000.00
GENI income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -55470000.00
GENI income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -55470000.00
GENI cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -55470000.00
GENI income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -55470000.00
GENI cash_flow (quarterly, 2026-03-31) — Net Intangibles Purchase And Sale: -84000.00
GENI income_statement (quarterly, 2026-03-31) — Net Interest Income: -928000.00
GENI cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: 0.00
GENI cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: 0.00
GENI income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -928000.00
GENI balance_sheet (quarterly, 2026-03-31) — Net PPE: 62915000.00
GENI cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -5338000.00
GENI balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 214022000.00
GENI balance_sheet (quarterly, 2026-03-31) — Non Current Accounts Receivable: 814000.00
GENI balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Assets: 3087000.00
GENI balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Liabilities: 6787000.00
GENI balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 1696000.00
GENI balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 6787000.00
GENI balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 1599000.00
GENI income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -14682000.00
GENI income_statement (quarterly, 2026-03-31) — Normalized Income: -36491060.04
GENI cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -66413000.00
GENI cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: 9368000.00
GENI income_statement (quarterly, 2026-03-31) — Operating Income: -35662000.00
GENI income_statement (quarterly, 2026-03-31) — Operating Revenue: 187952000.00
GENI balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 257538176.00
GENI balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 3611000.00
GENI balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: -45418000.00
GENI income_statement (quarterly, 2026-03-31) — Other Gand A: 53915000.00
GENI income_statement (quarterly, 2026-03-31) — Other Income Expense: -19008000.00
GENI balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 143028000.00
GENI cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: -12325000.00
GENI balance_sheet (quarterly, 2026-03-31) — Other Payable: 12928000.00
GENI balance_sheet (quarterly, 2026-03-31) — Other Properties: 62915000.00
GENI balance_sheet (quarterly, 2026-03-31) — Other Receivables: 55941000.00
GENI balance_sheet (quarterly, 2026-03-31) — Payables: 77428000.00
GENI balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 190344000.00
GENI balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 64527000.00
GENI income_statement (quarterly, 2026-03-31) — Pretax Income: -55598000.00
GENI cash_flow (quarterly, 2026-03-31) — Provisionand Write Offof Assets: 747000.00
GENI cash_flow (quarterly, 2026-03-31) — Purchase Of Intangibles: -84000.00
GENI cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -5338000.00
GENI balance_sheet (quarterly, 2026-03-31) — Receivables: 173636000.00
GENI income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 144628000.00
GENI income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 20980000.00
GENI cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: 0.00
GENI income_statement (quarterly, 2026-03-31) — Research And Development: 11402000.00
GENI income_statement (quarterly, 2026-03-31) — Restructuring And Mergern Acquisition: 7503000.00
GENI balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -1254578000.00
GENI income_statement (quarterly, 2026-03-31) — Selling And Marketing Expense: 13669000.00
GENI income_statement (quarterly, 2026-03-31) — Selling General And Administration: 67584000.00
GENI balance_sheet (quarterly, 2026-03-31) — Share Issued: 261644124.00
GENI income_statement (quarterly, 2026-03-31) — Special Income Charges: -9311000.00
GENI cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 21258000.00
GENI balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 695099000.00
GENI balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 214022000.00
GENI income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -29060.04
GENI income_statement (quarterly, 2026-03-31) — Tax Provision: -85000.00
GENI income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.00
GENI balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 7799000.00
GENI balance_sheet (quarterly, 2026-03-31) — Total Assets: 1017668000.00
GENI balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 695099000.00
GENI balance_sheet (quarterly, 2026-03-31) — Total Debt: 30550000.00
GENI balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 695099000.00
GENI income_statement (quarterly, 2026-03-31) — Total Expenses: 223614000.00
GENI balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 322569000.00
GENI balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 580435000.00
GENI balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 48612000.00
GENI income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: -43165000.00
GENI balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 3250000.00
GENI income_statement (quarterly, 2026-03-31) — Total Unusual Items: -19008000.00
GENI income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -19008000.00
GENI balance_sheet (quarterly, 2026-03-31) — Tradeand Other Payables Non Current: 16286000.00
GENI balance_sheet (quarterly, 2026-03-31) — Treasury Shares Number: 4105948.00
GENI balance_sheet (quarterly, 2026-03-31) — Treasury Stock: 17653000.00
GENI balance_sheet (quarterly, 2026-03-31) — Working Capital: 163276000.00
GENI income_statement (quarterly, 2026-03-31) — Write Off: 1735000.00
GENI.L income_statement (annual, 2021-12-31) — +Operating Expense: 4127000.00
GENI.L income_statement (annual, 2021-12-31) — +Total Revenue: 1154000.00
GENI.L balance_sheet (annual, 2021-12-31) — Accounts Payable: 345000.00
GENI.L balance_sheet (annual, 2021-12-31) — Accounts Receivable: 234000.00
GENI.L balance_sheet (annual, 2021-12-31) — Accumulated Depreciation: -9000.00
GENI.L balance_sheet (annual, 2021-12-31) — Additional Paid In Capital: 15551000.00
GENI.L income_statement (annual, 2021-12-31) — Amortization: 29000.00
GENI.L cash_flow (annual, 2021-12-31) — Amortization Cash Flow: 29000.00
GENI.L income_statement (annual, 2021-12-31) — Basic Average Shares: 50552205.00
GENI.L income_statement (annual, 2021-12-31) — Basic EPS: -0.08
GENI.L cash_flow (annual, 2021-12-31) — Beginning Cash Position: 2003000.00
GENI.L balance_sheet (annual, 2021-12-31) — Buildings And Improvements: 0.00
GENI.L cash_flow (annual, 2021-12-31) — Capital Expenditure: -145000.00
GENI.L balance_sheet (annual, 2021-12-31) — Capital Lease Obligations: 0.00
GENI.L balance_sheet (annual, 2021-12-31) — Capital Stock: 958000.00
GENI.L balance_sheet (annual, 2021-12-31) — Cash And Cash Equivalents: 14554000.00
GENI.L balance_sheet (annual, 2021-12-31) — Cash Cash Equivalents And Short Term Investments: 14558000.00
GENI.L cash_flow (annual, 2021-12-31) — Change In Inventory: 4000.00
GENI.L cash_flow (annual, 2021-12-31) — Change In Other Current Assets: -2000.00
GENI.L cash_flow (annual, 2021-12-31) — Change In Payable: 922000.00
GENI.L cash_flow (annual, 2021-12-31) — Change In Receivables: -150000.00
GENI.L cash_flow (annual, 2021-12-31) — Change In Working Capital: 774000.00
GENI.L cash_flow (annual, 2021-12-31) — Changes In Cash: 12617000.00
GENI.L balance_sheet (annual, 2021-12-31) — Common Stock: 958000.00
GENI.L balance_sheet (annual, 2021-12-31) — Common Stock Equity: 13718000.00
GENI.L cash_flow (annual, 2021-12-31) — Common Stock Issuance: 15856000.00
GENI.L income_statement (annual, 2021-12-31) — Cost Of Revenue: 561000.00
GENI.L balance_sheet (annual, 2021-12-31) — Current Assets: 14971000.00
GENI.L balance_sheet (annual, 2021-12-31) — Current Capital Lease Obligation: 0.00
GENI.L balance_sheet (annual, 2021-12-31) — Current Debt And Capital Lease Obligation: 0.00
GENI.L balance_sheet (annual, 2021-12-31) — Current Deferred Taxes Liabilities: 6000.00
GENI.L balance_sheet (annual, 2021-12-31) — Current Liabilities: 831000.00
GENI.L cash_flow (annual, 2021-12-31) — Deferred Tax: 6000.00
GENI.L cash_flow (annual, 2021-12-31) — Depreciation: 6000.00
GENI.L cash_flow (annual, 2021-12-31) — Depreciation And Amortization: 35000.00
GENI.L income_statement (annual, 2021-12-31) — Depreciation And Amortization In Income Statement: 35000.00
GENI.L income_statement (annual, 2021-12-31) — Depreciation Income Statement: 6000.00
GENI.L income_statement (annual, 2021-12-31) — Diluted Average Shares: 50552205.00
GENI.L income_statement (annual, 2021-12-31) — Diluted EPS: -0.08
GENI.L income_statement (annual, 2021-12-31) — Diluted NI Availto Com Stockholders: -4142000.00
GENI.L income_statement (annual, 2021-12-31) — EBIT: -4136000.00
GENI.L income_statement (annual, 2021-12-31) — EBITDA: -4101000.00
GENI.L cash_flow (annual, 2021-12-31) — Effect Of Exchange Rate Changes: -66000.00
GENI.L cash_flow (annual, 2021-12-31) — End Cash Position: 14554000.00
GENI.L cash_flow (annual, 2021-12-31) — Financing Cash Flow: 15856000.00
GENI.L cash_flow (annual, 2021-12-31) — Free Cash Flow: -3239000.00
GENI.L cash_flow (annual, 2021-12-31) — Gain Loss On Sale Of PPE: 19000.00
GENI.L income_statement (annual, 2021-12-31) — General And Administrative Expense: 2008000.00
GENI.L balance_sheet (annual, 2021-12-31) — Goodwill: 0.00
GENI.L balance_sheet (annual, 2021-12-31) — Goodwill And Other Intangible Assets: 193000.00
GENI.L balance_sheet (annual, 2021-12-31) — Gross PPE: 55000.00
GENI.L income_statement (annual, 2021-12-31) — Gross Profit: 593000.00
GENI.L income_statement (annual, 2021-12-31) — Interest Expense: 0.00
GENI.L income_statement (annual, 2021-12-31) — Interest Expense Non Operating: 0.00
GENI.L income_statement (annual, 2021-12-31) — Interest Income: 8000.00
GENI.L income_statement (annual, 2021-12-31) — Interest Income Non Operating: 8000.00
GENI.L balance_sheet (annual, 2021-12-31) — Inventory: 14000.00
GENI.L balance_sheet (annual, 2021-12-31) — Invested Capital: 13718000.00
GENI.L cash_flow (annual, 2021-12-31) — Investing Cash Flow: -145000.00
GENI.L cash_flow (annual, 2021-12-31) — Issuance Of Capital Stock: 15856000.00
GENI.L balance_sheet (annual, 2021-12-31) — Long Term Capital Lease Obligation: 0.00
GENI.L balance_sheet (annual, 2021-12-31) — Long Term Debt And Capital Lease Obligation: 0.00
GENI.L balance_sheet (annual, 2021-12-31) — Machinery Furniture Equipment: 55000.00
GENI.L cash_flow (annual, 2021-12-31) — Net Common Stock Issuance: 15856000.00
GENI.L cash_flow (annual, 2021-12-31) — Net Foreign Currency Exchange Gain Loss: 136000.00
GENI.L income_statement (annual, 2021-12-31) — Net Income: -4142000.00
GENI.L income_statement (annual, 2021-12-31) — Net Income Common Stockholders: -4142000.00
GENI.L income_statement (annual, 2021-12-31) — Net Income Continuous Operations: -4142000.00
GENI.L income_statement (annual, 2021-12-31) — Net Income From Continuing And Discontinued Operation: -4142000.00
GENI.L income_statement (annual, 2021-12-31) — Net Income From Continuing Operation Net Minority Interest: -4142000.00
GENI.L cash_flow (annual, 2021-12-31) — Net Income From Continuing Operations: -4137000.00
GENI.L income_statement (annual, 2021-12-31) — Net Income Including Noncontrolling Interests: -4142000.00
GENI.L cash_flow (annual, 2021-12-31) — Net Intangibles Purchase And Sale: -104000.00
GENI.L income_statement (annual, 2021-12-31) — Net Interest Income: 8000.00
GENI.L income_statement (annual, 2021-12-31) — Net Non Operating Interest Income Expense: 8000.00
GENI.L balance_sheet (annual, 2021-12-31) — Net PPE: 46000.00
GENI.L cash_flow (annual, 2021-12-31) — Net PPE Purchase And Sale: -41000.00
GENI.L balance_sheet (annual, 2021-12-31) — Net Tangible Assets: 13525000.00
GENI.L income_statement (annual, 2021-12-31) — Normalized EBITDA: -3489000.00
GENI.L income_statement (annual, 2021-12-31) — Normalized Income: -3646280.00
GENI.L cash_flow (annual, 2021-12-31) — Operating Cash Flow: -3094000.00
GENI.L income_statement (annual, 2021-12-31) — Operating Income: -3534000.00
GENI.L income_statement (annual, 2021-12-31) — Operating Revenue: 1154000.00